Showing results (71-80 of 172) with videos related to

Sort By:
Pageof 18
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 26, 2022
Evaluation of diagnostic and treatment approaches to acute dyspnea in a palliative care setting among medical doctors with different educational levelsKlaus Hackner, Magdalena Heim, Eva Katharina Masel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2020
Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in HumansAndreas Stadlbauer, Thomas M Kinfe, Ilker Eyüpoglu, et al.
The Journal of Biological Chemistry|April 25, 2006
Activated Jak2 with the V617F point mutation promotes G1/S phase transitionChristoph Walz, Brian J Crowley, Heidi E Hudon, et al.
Pain|September 15, 2004
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancerJean-Jacques Body, Ingo J Diel, Richard Bell, et al.
Experimental Hematology|March 8, 2002
Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implicationsYu-Tzu Tai, Klaus Podar, Stine-Kathrein Kraeft, et al.
Blood|July 3, 2009
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repairMargret S Fernandes, Mamatha M Reddy, Jeffrey R Gonneville, et al.
Blood|June 26, 2004
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cellsDharminder Chauhan, Guilan Li, Klaus Podar, et al.
British Journal of Haematology|February 21, 2006
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myelomaShaji Kumar, Noopur Raje, Teru Hideshima, et al.
Oncogene|November 25, 2003
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.
Cancer Research|October 20, 2004
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomibKlaus Podar, Reshma Shringarpure, Yu-Tzu Tai, et al.
Pageof 18